Loading…
Underlying
Underlying Price
$6.01
Type
Call
Strike
7.5
Expiration
Nov 20, 2026
DTE
7d
Moneyness
OTM
Intrinsic
$0.00
IBRX 7.5 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Nov 13, 2026 | 0d | $1.50 | +0.00% | 1 | 505 |
| Nov 20, 2026 | 7d | $1.27 | +0.00% | 45 | 329 |
| Nov 27, 2026 | 14d | $1.35 | -27.42% | 50 | 168 |
| Dec 4, 2026 | 21d | $1.51 | -13.71% | 11 | 81 |
| Dec 11, 2026 | 28d | $1.58 | +0.00% | 12 | 34 |
| Dec 24, 2026 | 41d | — | — | 0 | 0 |
| Dec 31, 2026 | 48d | — | — | 0 | 0 |
| Jan 15, 2027 | 63d | $1.77 | -23.04% | 25 | 21,172 |
| Jan 21, 2028 | 434d | $3.14 | -6.82% | 6 | 18,082 |
IBRX Nearby Strikes · Nov 20, 2026
| Strike | Last | Change | Vol | Open Int | Moneyness |
|---|---|---|---|---|---|
| 4.5 C | $4.19 | +0.00% | 6 | 6 | ITM |
| 5 C | $4.85 | -6.73% | 4 | 8 | ITM |
| 5.5 C | — | — | 0 | 23 | ITM |
| 6 C | $2.44 | -30.29% | 2 | 330 | ITM |
| 6.5 C | $2.08 | +0.00% | 2 | 151 | OTM |
| 7 C | $1.50 | -21.05% | 6 | 2,283 | OTM |
| 7.5 C | $1.27 | +0.00% | 45 | 329 | OTM |
| 8 C | $0.85 | -34.62% | 178 | 2,043 | OTM |
| 8.5 C | $0.70 | -11.39% | 21 | 160 | OTM |
| 9 C | $0.57 | -37.36% | 196 | 6,793 | OTM |
| 9.5 C | $0.46 | -30.30% | 73 | 78 | OTM |
| 10 C | $0.33 | -49.23% | 108 | 8,626 | OTM |
| 10.5 C | $0.38 | -24.00% | 7 | 40 | OTM |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.